Search company, investor...

Innovate Technologies In Biological System

innoprot.com

Stage

Other Investors | Alive

About Innovate Technologies In Biological System

Innoprot tGFP-BACE1 HEK293 Cell Line CB2 Internalization Assay Cell Line hGR Nuclear Translocation Assay Cell Line Human Cardiac Myocytes Assay Development Neurotoxicity Assay induced by beta amyloid NEWS Innoprot has been awarded on the Bizkaia Ekinez Prizes 05/06/2009 Innoprot has been awarded on the Bizkaia Ekinez Prizes with the "Gaztedi Prize"

Headquarters Location

Pais Vasco (Basque Country)

Spain

Missing: Innovate Technologies In Biological System's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Innovate Technologies In Biological System's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Innovate Technologies In Biological System Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Innovate Technologies In Biological System Rank

Innovate Technologies In Biological System Frequently Asked Questions (FAQ)

  • What is Innovate Technologies In Biological System's latest funding round?

    Innovate Technologies In Biological System's latest funding round is Other Investors.

  • Who are the investors of Innovate Technologies In Biological System?

    Investors of Innovate Technologies In Biological System include Seed Capital Bizkaia.

  • Who are Innovate Technologies In Biological System's competitors?

    Competitors of Innovate Technologies In Biological System include Armgo Pharma, Cognate BioServices, BioGX, HTG Molecular Diagnostics, Amnis Corporation and 12 more.

Compare Innovate Technologies In Biological System to Competitors

e
eSionic

eSionic, formerly Zettacore, enables devices and systems that consume less materials, generate less waste, have longer life, operate with higher reliability, use less energy, integrate seamlessly, operate more efficiently and cost less.

R
RenaMed Biologics

RenaMed Biologics, a University of Michigan spin-out from the late 90s, is a clinical stage cellular therapy company dedicated to the design, development, and commercialization of human cell replacement systems. RenaMed's products provide targeted and kidney cell therapy for patients suffering from severe inflammatory disease states such as Acute Renal Failure.

I
InvivoSciences

Invivo Sciences technology aims to bridge the gap in preclinical research performed using animal models and cell culture systems. Per the company, the advances in lab-automation coupled with the company's expertise in tissue engineering allows InvivoSciences to commercialize fast, reliable, and cost effective screening systems.

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

G
Gahaga Biosciences

Gahaga Biosciences was founded in 2006 to commercialize a method for the isolation of stem cells from placental and umbilical tissues to be used in basic research. Gahaga Biosciences intends to provide stem cells to the research and commercial markets which are valued as a potential source of a range of types of tissue. Many scientists say embryonic stem cells are generally more versatile than adult cells, although they continue to explore the possibilities of adult stem cells. The company believe that placental and umbilical stems cells are an ideal model system for conducting basic research on cell differentiation and regulation. Gahaga Biosciences seeks to supply researchers with materials to focus on the basic mechanisms of stem cell differentiation - how stem cells make the decision to move from their stem cell state into a more committed phenotype. Gahaga also seeks to exploit the company's experience in other methods such as pancreatic islets.

N
NeuroGenomeX

NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.